[go: up one dir, main page]

BRPI0414008B8 - compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula - Google Patents

compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula

Info

Publication number
BRPI0414008B8
BRPI0414008B8 BRPI0414008A BRPI0414008A BRPI0414008B8 BR PI0414008 B8 BRPI0414008 B8 BR PI0414008B8 BR PI0414008 A BRPI0414008 A BR PI0414008A BR PI0414008 A BRPI0414008 A BR PI0414008A BR PI0414008 B8 BRPI0414008 B8 BR PI0414008B8
Authority
BR
Brazil
Prior art keywords
thrombopoietin receptor
bind
compounds
activating
compositions
Prior art date
Application number
BRPI0414008A
Other languages
English (en)
Inventor
R Macdonald Brian
John Yurkow Edward
Kenneth Weis Jeffery
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414008(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BRPI0414008A publication Critical patent/BRPI0414008A/pt
Publication of BRPI0414008B1 publication Critical patent/BRPI0414008B1/pt
Publication of BRPI0414008B8 publication Critical patent/BRPI0414008B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)

Abstract

"peptídeos e compostos que se ligam a um receptor". a presente invenção refere-se a peptídeos e compostos que se ligam a e ativam o receptor de trombopoietina (c-mpl ou tpo-r) ou, de outro modo, atuam como um agonista de tpo que são descritos.
BRPI0414008A 2003-08-28 2004-08-13 compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula BRPI0414008B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
US60/498,740 2003-08-28
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Publications (3)

Publication Number Publication Date
BRPI0414008A BRPI0414008A (pt) 2006-10-24
BRPI0414008B1 BRPI0414008B1 (pt) 2018-05-15
BRPI0414008B8 true BRPI0414008B8 (pt) 2021-05-25

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414008A BRPI0414008B8 (pt) 2003-08-28 2004-08-13 compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula

Country Status (32)

Country Link
US (1) US7576056B2 (pt)
EP (1) EP1675606B1 (pt)
JP (1) JP4848277B2 (pt)
KR (2) KR20120078742A (pt)
CN (2) CN102241742B (pt)
AR (1) AR045530A1 (pt)
AU (1) AU2004270656B2 (pt)
BR (1) BRPI0414008B8 (pt)
CA (1) CA2537421C (pt)
CY (1) CY1118965T1 (pt)
DK (1) DK1675606T3 (pt)
EA (1) EA009286B1 (pt)
EC (1) ECSP066396A (pt)
ES (1) ES2626107T3 (pt)
HR (1) HRP20170810T1 (pt)
HU (1) HUE032370T2 (pt)
IL (1) IL173965A (pt)
IS (1) IS8300A (pt)
LT (1) LT1675606T (pt)
ME (1) ME00313B (pt)
MX (1) MXPA06002292A (pt)
NO (1) NO344233B1 (pt)
NZ (1) NZ545455A (pt)
PL (1) PL1675606T3 (pt)
PT (1) PT1675606T (pt)
RS (2) RS20060141A (pt)
SG (1) SG131110A1 (pt)
SI (1) SI1675606T1 (pt)
TW (1) TWI348375B (pt)
UA (1) UA82710C2 (pt)
WO (1) WO2005023834A2 (pt)
ZA (1) ZA200602495B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
DE122009000039I1 (de) 1998-10-23 2009-11-05 Kirin Amgen Inc Thrombopoietin substitute
WO2004026332A1 (en) * 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
MXPA06002292A (es) 2003-08-28 2006-09-04 Johnson & Johnson Peptidos y compuestos que se unen a un receptor.
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
CA2635498A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
AR059573A1 (es) * 2006-02-14 2008-04-16 Janssen Pharmaceutica Nv Uso de compuestos peptidicos de tpo y composiciones farmaceuticas en el tratamiento de la anemia
DK1984014T3 (da) * 2006-02-14 2014-09-15 Janssen Pharmaceutica Nv Anvendelse af tpo-peptidforbindelser og farmaceutiske sammensætninger ved behandlingen af anæmi
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ES2729622T3 (es) * 2008-06-03 2019-11-05 Janssen Pharmaceutica Nv Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer
CN103635514B (zh) 2011-06-23 2016-01-20 株式会社岛津制作所 支链型两亲性嵌段聚合物、使用其的分子聚集体及药物输送系统
BR112020001367A2 (pt) 2017-07-26 2020-08-11 Janssen Pharmaceutica N.V. métodos de proteção da integridade vascular induzida por terapia de radiação direcionada
KR20210120037A (ko) 2019-01-25 2021-10-06 잔센파마슈티카엔.브이. 수포제 및 가성 가스의 독성 영향 경감 방법
MA54820A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
MA54821A (fr) * 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
IL311797A (en) 2021-10-01 2024-05-01 Albert Einstein College Medicine Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ES2181691T5 (es) 1992-06-11 2007-10-01 Alkermes Controlled Therapeutics, Inc. Sistema de distribucion de proteina eritropoyetina.
CA2150371C (en) * 1992-12-11 2002-09-17 Dov Borovsky Materials and methods for control of pests
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
NZ281482A (en) 1994-02-14 2000-09-29 Univ Washington The stimulation of erythropoiesis using thrombopoietin and erythropoietin
BR9408534A (pt) 1994-02-14 1997-08-05 Zymogenetics Inc Proteína isolada molécula de polinucleotídeos e de dna isolada vetor de expressão célula cultivada mam'fero não humano composição farmacêutica anticorpo sonda e processos para produzir uma proteina hematopoiética para estimular a produção de plaquetas em um mamifero e a proliferação celular para detectar em uma mistura de moléculas de dna uma molécula de dna e para purificar trombopoietina
EP0668352A1 (en) 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
KR100203824B1 (ko) 1994-03-31 1999-06-15 스티븐 엠. 오드리 거핵구 성장 및 분화를 자극하기 위한 조성물 및방법
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
KR100376150B1 (ko) * 1994-11-04 2003-11-01 산텐 세이야꾸 가부시키가이샤 히드록시기를함유하는1,3-디알킬우레아유도체
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1996017062A1 (en) 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
CA2194070A1 (en) 1995-04-26 1996-10-31 Haruhiko Yokoi Novel polypeptides
KR100436680B1 (ko) * 1995-06-07 2004-09-18 글락소 그룹 리미티드 트롬보포이에틴 수용체에 결합하는 펩티드 및 화합물
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
AU771460B2 (en) 1999-09-24 2004-03-25 Smithkline Beecham Corporation Thrombopoietin mimetics
ATE339442T1 (de) * 2000-12-22 2006-10-15 Ipsen Mfg Ireland Ltd Verfahren für die synthese eines lhrh peptides
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
WO2004026332A1 (en) * 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
MXPA06002292A (es) 2003-08-28 2006-09-04 Johnson & Johnson Peptidos y compuestos que se unen a un receptor.

Also Published As

Publication number Publication date
AR045530A1 (es) 2005-11-02
EP1675606B1 (en) 2017-04-05
ECSP066396A (es) 2006-08-30
EP1675606A2 (en) 2006-07-05
CN102241742A (zh) 2011-11-16
TW200517103A (en) 2005-06-01
KR20070017942A (ko) 2007-02-13
IL173965A (en) 2015-10-29
CN102241742B (zh) 2014-04-02
CA2537421A1 (en) 2005-03-17
RS20060141A (en) 2008-08-07
US20050137133A1 (en) 2005-06-23
EA200600477A1 (ru) 2007-02-27
CA2537421C (en) 2011-09-27
MXPA06002292A (es) 2006-09-04
NO20061346L (no) 2006-05-22
CN1871022A (zh) 2006-11-29
IL173965A0 (en) 2006-07-05
ME00313B (me) 2011-05-10
WO2005023834A2 (en) 2005-03-17
HRP20170810T1 (hr) 2017-08-11
SI1675606T1 (sl) 2017-07-31
NZ545455A (en) 2009-02-28
ES2626107T3 (es) 2017-07-24
AU2004270656A1 (en) 2005-03-17
JP2007504132A (ja) 2007-03-01
UA82710C2 (uk) 2008-05-12
ZA200602495B (en) 2007-06-27
LT1675606T (lt) 2017-11-10
HUE032370T2 (en) 2017-09-28
MEP48508A (en) 2011-02-10
TWI348375B (en) 2011-09-11
EA009286B1 (ru) 2007-12-28
BRPI0414008B1 (pt) 2018-05-15
AU2004270656B2 (en) 2011-03-10
KR101183875B1 (ko) 2012-09-27
WO2005023834A3 (en) 2005-05-06
BRPI0414008A (pt) 2006-10-24
CY1118965T1 (el) 2018-01-10
KR20120078742A (ko) 2012-07-10
PT1675606T (pt) 2017-05-22
IS8300A (is) 2006-02-14
RS56387B1 (sr) 2017-12-29
CN1871022B (zh) 2011-07-06
NO344233B1 (no) 2019-10-14
PL1675606T3 (pl) 2017-08-31
HK1096873A1 (en) 2007-06-15
US7576056B2 (en) 2009-08-18
SG131110A1 (en) 2007-04-26
JP4848277B2 (ja) 2011-12-28
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30

Similar Documents

Publication Publication Date Title
BRPI0414008B8 (pt) compostos que se ligam a um receptor de trombopoietina, composições e métodos in vitro para ativação de um receptor de trombopoietina em uma célula
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
WO2006129085A3 (en) High affinity melan-a t cell receptors
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
JO2859B1 (en) Peptides and compounds that are associated with a receptor
TW200800967A (en) Benzimidazole thiophene compounds
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
BRPI0501450A (pt) Composição funcional, e, artigo
ATE478069T1 (de) 3,4-dihydro-2h-benzoä1,4üoxazin- und 3,4-dihydro- 2h-benzoä1,4üthiazin-verbindungen als alpha2c- adrenorezeptor-antagonisten
BRPI0511008A (pt) agentes de ligação de il-13
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
TW200643453A (en) Polymerizable composition comprising low molecular weight organic component
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
UA94705C2 (ru) Средства против эндопаразитов
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
EA200800820A1 (ru) Композиция с замедленным высвобождением и ее применение
EA200701892A1 (ru) Композиции, содержащие связанную воду и компоненты, помещённые в водочувствительную основу
UA92180C2 (en) Benzimidazole thiophene compounds as plk inhibitors
TW200730289A (en) Fluxing compositions containing benzotriazoles
DE602006020781D1 (en) T-helper antigenic determinant (thd) peptide

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF